{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T05:24:26Z","timestamp":1733376266307,"version":"3.30.1"},"reference-count":34,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:p>Vesicular monoamine transporter 2 inhibitors (VMAT2i) are currently Food and Drug Administration\u2013approved for the treatment of Huntington disease chorea and tardive dyskinesia. Additionally, they are often used for other hyperkinetic movement disorders in clinical practice. Due to a lack of head-to-head clinical trials, management of VMAT2i in the clinical setting may be unclear and rely on the clinical experience of the practitioner. Due to the limited distribution model, which typically requires VMAT2i to be dispensed by specialty pharmacies, access and initiation of treatment may present as barriers. Patient cases allow for the exploration of switching between VMAT2i, alternative routes of administration, utilization in pediatric and off-label conditions, and how to successfully initiate and monitor a patient on VMAT2i therapy.<\/jats:p>","DOI":"10.9740\/mhc.2024.12.304","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:30:38Z","timestamp":1733272238000},"page":"304-312","source":"Crossref","is-referenced-by-count":0,"title":["Clinical experience and treatment considerations with vesicular monoamine transport 2 inhibitors"],"prefix":"10.9740","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2247-7307","authenticated-orcid":true,"given":"Kayla","family":"Johnson","sequence":"first","affiliation":[{"name":"(Corresponding author) Clinical Pharmacist Specialist, Vanderbilt Specialty Pharmacy Services, Nashville, Tennessee, kayla.d.johnson@vumc.org"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4719","reference":[{"issue":"3","key":"i2168-9709-14-6-304-b01","series-title":"Iran J Child Neurol","first-page":"29","article-title":"A brief review on the role of vesicular monoamine transporter2 inhibitors in hyperkinetic movement disorders","volume":"15","author":"Nikkhah","year":"2021","unstructured":"Nikkhah A. A brief review on the role of vesicular monoamine transporter2 inhibitors in hyperkinetic movement disorders. Iran J Child Neurol. 2021;15(3):29-33. DOI: 10.22037\/ijcn.v15i3.33144"},{"key":"i2168-9709-14-6-304-b02","article-title":"INGREZZA (valbenazine) capsules, for oral use and INGREZZA SPRINKLE (valbenazine) capsules, for oral use","author":"Neurocrine Biosciences, Inc","year":"2017","unstructured":"Neurocrine Biosciences, Inc. INGREZZA (valbenazine) capsules, for oral use and INGREZZA SPRINKLE (valbenazine) capsules, for oral use. 2017 [rev. 2024 Apr; cited 2024 May 1]. Available from: https:\/\/www.neurocrine.com\/assets\/2024\/04\/INGREZZA-Full-Prescribing-Information_PI_Approved.pdf"},{"key":"i2168-9709-14-6-304-b03","article-title":"AUSTEDO XR (deutetrabenazine) extended-release tablets, for oral use and AUSTEDO (deutetrabenazine) tablets, for oral use","author":"Teva Neuroscience, Inc.","year":"2017","unstructured":"Teva Neuroscience, Inc. AUSTEDO XR (deutetrabenazine) extended-release tablets, for oral use and AUSTEDO (deutetrabenazine) tablets, for oral use. 2017 [rev 2023 Sep; cited 2024 Apr 26]. In: DailyMed [Internet]. [2005] [about 47 p.]. National Library of Medicine (US). Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=7ea3c60a-45c7-44cc-afc2-d87fa53993c0"},{"key":"i2168-9709-14-6-304-b04","article-title":"XENAZINE (tetrabenazine) tablets, for oral use","author":"Lundbeck Pharmaceuticals, LLC.","year":"2008","unstructured":"Lundbeck Pharmaceuticals, LLC. XENAZINE (tetrabenazine) tablets, for oral use. 2008 [rev 2019 Nov; cited 2024 Apr 26]. In: DailyMed [Internet]. [2005] [about 19 p.]. National Library of Medicine (US). Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=ac768bab-8afa-4446-bc7f-caeeffec0cda"},{"issue":"4","key":"i2168-9709-14-6-304-b05","series-title":"Clinical Translational Sci","first-page":"707","article-title":"Pharmacokinetic and metabolic profile of deutetrabenazine (TEV\u201050717) compared with tetrabenazine in healthy volunteers","volume":"13","author":"Schneider","year":"2020","unstructured":"Schneider F,\nBradbury M,\nBaillie TA,\nStamler D,\nHellriegel E,\nCox DS, et al. Pharmacokinetic and metabolic profile of deutetrabenazine (TEV\u201050717) compared with tetrabenazine in healthy volunteers. Clinical Translational Sci. 2020;13(4):707-17. DOI: 10.1111\/cts.12754"},{"issue":"3","key":"i2168-9709-14-6-304-b06","series-title":"Clin Transl Sci","first-page":"512","article-title":"Pharmacokinetics, safety and tolerability of valbenazine in Korean CYP2D6 normal and intermediate metabolizers","volume":"16","author":"Chung","year":"2023","unstructured":"Chung WK,\nHwang I,\nKim B,\nJung J,\nYu KS,\nJang IJ, et al. Pharmacokinetics, safety and tolerability of valbenazine in Korean CYP2D6 normal and intermediate metabolizers. Clin Transl Sci. 2023;16(3):512-23. DOI: 10.1111\/cts.13466"},{"issue":"6","key":"i2168-9709-14-6-304-b07","series-title":"Psychology & Health","first-page":"726","article-title":"Medication nonadherence: health impact, prevalence, correlates and interventions","volume":"38","author":"Stewart","year":"2023","unstructured":"Stewart SJF,\nMoon Z,\nHorne R. Medication nonadherence: health impact, prevalence, correlates and interventions. Psychology & Health. 2023;38(6):726-65. DOI: 10.1080\/08870446.2022.2144923"},{"issue":"1","key":"i2168-9709-14-6-304-b08","series-title":"J Clin Mov Disord","first-page":"3","article-title":"Indirect tolerability comparison of deutetrabenazine and tetrabenazine for Huntington disease","volume":"4","author":"Claassen","year":"2017","unstructured":"Claassen DO,\nCarroll B,\nDe Boer LM,\nWu E,\nAyyagari R,\nGandhi S, et al. Indirect tolerability comparison of deutetrabenazine and tetrabenazine for Huntington disease. J Clin Mov Disord. 2017;4(1):3. DOI: 10.1186\/s40734-017-0051-5"},{"issue":"suppl 1","key":"i2168-9709-14-6-304-b09","series-title":"Mov Disord","article-title":"Indirect treatment comparison of valbenazine with deutetrabenazine for improvement in total maximal chorea score in Huntington disease [abstract]","volume":"38","author":"Mehanna","year":"2023","unstructured":"Mehanna R,\nStimming EF,\nHaubenberger D,\nKlepitskaya O,\nAggarwal S,\nKumar S, et al. Indirect treatment comparison of valbenazine with deutetrabenazine for improvement in total maximal chorea score in Huntington disease [abstract]. Mov Disord. 2023;38(suppl 1). Available from: https:\/\/www.mdsabstracts.org\/abstract\/indirect-treatment-comparison-of-valbenazine-with-deutetrabenazine-for-improvement-in-total-maximal-chorea-score-in-huntington-disease\/"},{"issue":"13","key":"i2168-9709-14-6-304-b10","series-title":"J Comp Eff Res","first-page":"1077","article-title":"Indirect treatment comparison of valbenazine and deutetrabenazine efficacy and safety in tardive dyskinesia","volume":"8","author":"Aggarwal","year":"2019","unstructured":"Aggarwal S,\nSerbin M,\nYonan C. Indirect treatment comparison of valbenazine and deutetrabenazine efficacy and safety in tardive dyskinesia. J Comp Eff Res. 2019;8(13):1077-88. DOI: 10.2217\/cer-2019-0059"},{"issue":"8","key":"i2168-9709-14-6-304-b11","series-title":"JAMA Neurol","first-page":"977","article-title":"Safety of converting from tetrabenazine to deutetrabenazine for the treatment of chorea","volume":"74","author":"Frank","year":"2017","unstructured":"Frank S,\nStamler D,\nKayson E,\nClaassen DO,\nColcher A,\nDavis C, et al. Safety of converting from tetrabenazine to deutetrabenazine for the treatment of chorea. JAMA Neurol. 2017;74(8):977. DOI: 10.1001\/jamaneurol.2017.1352"},{"issue":"18","key":"i2168-9709-14-6-304-b12","series-title":"Am J Health Syst Pharm","first-page":"1477","article-title":"Crushing deutetrabenazine for treatment of tardive dyskinesia in a patient with severe orofacial symptoms: a case report","volume":"77","author":"Wietholter","year":"2020","unstructured":"Wietholter JP,\nSizemore J,\nPiechowski K. Crushing deutetrabenazine for treatment of tardive dyskinesia in a patient with severe orofacial symptoms: a case report. Am J Health Syst Pharm. 2020;77(18):1477-81. DOI: 10.1093\/ajhp\/zxaa205"},{"issue":"17","key":"i2168-9709-14-6-304-b13","series-title":"Am J Health Syst Pharm","first-page":"1551","article-title":"On crushing of deutetrabenazine tablets","volume":"78","author":"Knebel","year":"2021","unstructured":"Knebel H,\nAlexander J,\nWilhelm A,\nLoupe P,\nSchneider F,\nGordon MF. On crushing of deutetrabenazine tablets. Am J Health Syst Pharm. 2021;78(17):1551-2. DOI: 10.1093\/ajhp\/zxab130"},{"issue":"12","key":"i2168-9709-14-6-304-b14","series-title":"Clin Ther","first-page":"1222","article-title":"Crushing the contents of valbenazine capsules for potential addition to soft foods or administration via gastrostomy tube","volume":"45","author":"Sajatovic","year":"2023","unstructured":"Sajatovic M,\nPatel A,\nHebert M,\nMar A,\nMoore R,\nBristow A, et al. Crushing the contents of valbenazine capsules for potential addition to soft foods or administration via gastrostomy tube. Clin Ther. 2023;45(12):1222-7. DOI: 10.1016\/j.clinthera.2023.09.024"},{"key":"i2168-9709-14-6-304-b15","series-title":"Pharmacology & Therapeutics","first-page":"107580","article-title":"VMAT2 inhibitors for the treatment of hyperkinetic movement disorders","volume":"212","author":"Koch","year":"2020","unstructured":"Koch J,\nShi WX,\nDashtipour K. VMAT2 inhibitors for the treatment of hyperkinetic movement disorders. Pharmacology & Therapeutics. 2020;212:107580. DOI: 10.1016\/j.pharmthera.2020.107580"},{"key":"i2168-9709-14-6-304-b16","article-title":"2000 Feb 29 \u2013 Current. Identifier NCT04173260: An open-label study to define the safety, tolerability and clinical activity of deutetrabenazine (AUstedo) in adult study subjects with dystonia (AUDYT);","author":"ClinicalTrials.gov [Internet]. National Library of Medicine (US)","year":"2019","unstructured":"ClinicalTrials.gov [Internet]. National Library of Medicine (US). 2000 Feb 29 \u2013 Current. Identifier NCT04173260: An open-label study to define the safety, tolerability and clinical activity of deutetrabenazine (AUstedo) in adult study subjects with dystonia (AUDYT); 2019 Nov 21 [cited 2023 Nov 7]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04173260?term=deutetrabenazine&recrs=a&draw=2&rank=2"},{"key":"i2168-9709-14-6-304-b17","article-title":"2000 Feb 29 \u2013 Current. Identifier NCT05654870: Study to evaluate the efficacy, safety, and tolerability of valbenazine as an adjunctive treatment for schizophrenia","author":"ClinicalTrials.gov [Internet]. National Library of Medicine (US).","year":"2022","unstructured":"ClinicalTrials.gov [Internet]. National Library of Medicine (US). 2000 Feb 29 \u2013 Current. Identifier NCT05654870: Study to evaluate the efficacy, safety, and tolerability of valbenazine as an adjunctive treatment for schizophrenia; 2022 Dec 16 [cited 2023 Nov 7]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05654870?term=valbenazine&recrs=a&draw=2&rank=2"},{"key":"i2168-9709-14-6-304-b18","article-title":"2000 Feb 29 \u2013 Current. Identifier NCT05110157: Journey study: evaluate the efficacy, safety, and tolerability of valbenazine as adjunctive treatment for schizophrenia","author":"ClinicalTrials.gov [Internet]. National Library of Medicine (US).","year":"2021","unstructured":"ClinicalTrials.gov [Internet]. National Library of Medicine (US). 2000 Feb 29 \u2013 Current. Identifier NCT05110157: Journey study: evaluate the efficacy, safety, and tolerability of valbenazine as adjunctive treatment for schizophrenia; 2021 Nov 5 [cited 2023 Nov 7]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05110157?term=valbenazine&recrs=a&draw=2&rank=5"},{"key":"i2168-9709-14-6-304-b19","article-title":"2000 Feb 29 \u2013 Current. Identifier NCT05207085: Efficacy of valbenazine for the treatment of trichotillomania in adults","author":"ClinicalTrials.gov [Internet]. National Library of Medicine (US).","year":"2022","unstructured":"ClinicalTrials.gov [Internet]. National Library of Medicine (US). 2000 Feb 29 \u2013 Current. Identifier NCT05207085: Efficacy of valbenazine for the treatment of trichotillomania in adults; 2022 Jan 26 [cited 2023 Nov 7]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05207085?term=valbenazine&recrs=a&draw=2&rank=3"},{"key":"i2168-9709-14-6-304-b20","article-title":"2000 Feb 29 \u2013 Current. Identifier NCT05206513: Study to assess the efficacy, safety, and tolerability of valbenazine for the treatment of dyskinesia due to cerebral palsy","author":"ClinicalTrials.gov [Internet]. National Library of Medicine (US).","year":"2022","unstructured":"ClinicalTrials.gov [Internet]. National Library of Medicine (US). 2000 Feb 29 \u2013 Current. Identifier NCT05206513: Study to assess the efficacy, safety, and tolerability of valbenazine for the treatment of dyskinesia due to cerebral palsy; 2022 Jan 25 [cited 2023 Nov 7]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05206513?term=valbenazine&recrs=a&draw=2&rank=4"},{"issue":"4","key":"i2168-9709-14-6-304-b21","series-title":"Eur Child Adolesc Psychiatry","first-page":"173","article-title":"European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment","volume":"20","author":"Roessner","year":"2011","unstructured":"Roessner V,\nPlessen KJ,\nRothenberger A,\nLudolph AG,\nRizzo R,\nSkov L. et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry. 2011;20(4):173-96. DOI: 10.1007\/s00787-011-0163-7"},{"issue":"2","key":"i2168-9709-14-6-304-b22","series-title":"Clin Neuropharmacol","first-page":"37","article-title":"Real-world experience with VMAT2 inhibitors","volume":"42","author":"Niemann","year":"2019","unstructured":"Niemann N,\nJankovic J. Real-world experience with VMAT2 inhibitors. Clin Neuropharmacol. 2019;42(2):37-41. DOI: 10.1097\/WNF.0000000000000326"},{"issue":"9","key":"i2168-9709-14-6-304-b23","series-title":"J Neurol","first-page":"4518","article-title":"Real-world experience with VMAT2 inhibitors in Tourette syndrome","volume":"270","author":"Makhoul","year":"2023","unstructured":"Makhoul K,\nJankovic J. Real-world experience with VMAT2 inhibitors in Tourette syndrome. J Neurol. 2023;270(9):4518-22. DOI: 10.1007\/s00415-023-11769-0"},{"issue":"10","key":"i2168-9709-14-6-304-b24","series-title":"JAMA Netw Open","first-page":"e2128204","article-title":"Safety and efficacy of flexible-dose deutetrabenazine in children and adolescents with Tourette syndrome: a randomized clinical trial","volume":"4","author":"Jankovic","year":"2021","unstructured":"Jankovic J,\nCoffey B,\nClaassen DO,\nJimenez-Shahed J,\nGertz BJ,\nGarofalo EA, et al. Safety and efficacy of flexible-dose deutetrabenazine in children and adolescents with Tourette syndrome: a randomized clinical trial. JAMA Netw Open. 2021;4(10):e2128204. DOI: 10.1001\/jamanetworkopen.2021.28204"},{"issue":"10","key":"i2168-9709-14-6-304-b25","series-title":"JAMA Netw Open","first-page":"e2129397","article-title":"Efficacy and safety of fixed-dose deutetrabenazine in children and adolescents for tics associated with tourette syndrome: a randomized clinical trial","volume":"4","author":"Coffey","year":"2021","unstructured":"Coffey B,\nJankovic J,\nClaassen DO,\nJimenez-Shahed J,\nGertz B,\nGarofalo EA, et al. Efficacy and safety of fixed-dose deutetrabenazine in children and adolescents for tics associated with tourette syndrome: a randomized clinical trial. JAMA Netw Open. 2021;4(10):e2129397. DOI: 10.1001\/jamanetworkopen.2021.29397"},{"issue":"3","key":"i2168-9709-14-6-304-b26","series-title":"J Clin Psychiatry","first-page":"17cs11959","article-title":"Revisiting the abnormal involuntary movement scale: proceedings from the tardive dyskinesia assessment workshop","volume":"79","author":"Kane","year":"2018","unstructured":"Kane JM,\nCorrell CU,\nNierenberg AA,\nCaroff SN,\nSajatovic M. Tardive Dyskinesia Assessment Working Group. Revisiting the abnormal involuntary movement scale: proceedings from the tardive dyskinesia assessment workshop. J Clin Psychiatry. 2018;79(3):17cs11959. DOI: 10.4088\/JCP.17cs11959"},{"issue":"2","key":"i2168-9709-14-6-304-b27","series-title":"Movement Disorders","first-page":"136","article-title":"Unified Huntington\u2019s disease rating scale: Reliability and consistency","volume":"11","year":"1996","unstructured":"Unified Huntington\u2019s disease rating scale: Reliability and consistency. Movement Disorders. 1996;11(2):136-42. DOI: 10.1002\/mds.870110204"},{"key":"i2168-9709-14-6-304-b28","series-title":"Front Psychiatry","first-page":"626459","article-title":"Yale global tic severity scale (YGTSS): psychometric quality of the gold standard for tic assessment based on the large-scale EMTICS study","volume":"12","author":"Haas","year":"2021","unstructured":"Haas M,\nJakubovski E,\nFremer C,\nDietrich A,\nHoekstra PJ,\nJager B, et al. Yale global tic severity scale (YGTSS): psychometric quality of the gold standard for tic assessment based on the large-scale EMTICS study. Front Psychiatry. 2021;12:626459. DOI: 10.3389\/fpsyt.2021.626459"},{"issue":"8","key":"i2168-9709-14-6-304-b29","series-title":"Lancet Psychiatry","first-page":"595","article-title":"Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"4","author":"Anderson","year":"2017","unstructured":"Anderson KE,\nStamler D,\nDavis MD,\nFactor SA,\nHauser RA,\nIsojarvi J, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4(8):595-604. DOI: 10.1016\/S2215-0366(17)30236-5"},{"issue":"21","key":"i2168-9709-14-6-304-b30","series-title":"Neurology","first-page":"2003","article-title":"Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study","volume":"88","author":"Fernandez","year":"2017","unstructured":"Fernandez HH,\nFactor SA,\nHauser RA,\nJimenez-Shahed J,\nOndo WG,\nJarskog LF, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017;88(21):2003-10. DOI: 10.1212\/WNL.0000000000003960"},{"issue":"1","key":"i2168-9709-14-6-304-b31","series-title":"JAMA","first-page":"40","article-title":"Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial","volume":"316","author":"Huntington Study Group","year":"2016","unstructured":"Huntington Study Group. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA. 2016;316(1):40. DOI: 10.1001\/jama.2016.8655"},{"key":"i2168-9709-14-6-304-b32","series-title":"PLoS Curr","first-page":"RRN1283","article-title":"Use of tetrabenazine in Huntington disease patients on antidepressants or with advanced disease: results from the TETRA-HD study","volume":"3","author":"Dorsey","year":"2011","unstructured":"Dorsey R,\nBiglan K,\nEberly S,\nAuinger P,\nBrocht A,\nUmeh CC, et al. Use of tetrabenazine in Huntington disease patients on antidepressants or with advanced disease: results from the TETRA-HD study. PLoS Curr. 2011;3:RRN1283. DOI: 10.1371\/currents.RRN1283"},{"issue":"5","key":"i2168-9709-14-6-304-b33","series-title":"AJP","first-page":"476","article-title":"Kinect 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia","volume":"174","author":"Hauser","year":"2017","unstructured":"Hauser RA,\nFactor SA,\nMarder SR,\nKnesevich MA,\nRamirez PM,\nJimenez R, et al. Kinect 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. AJP. 2017;174(5):476-84. DOI: 10.1176\/appi.ajp.2017.16091037"},{"issue":"6","key":"i2168-9709-14-6-304-b34","series-title":"Lancet Neurol","first-page":"494","article-title":"Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington\u2019s disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"22","author":"Furr Stimming","year":"2023","unstructured":"Furr Stimming E,\nClaassen DO,\nKayson E,\nGoldstein J,\nMehanna R,\nZhang H, et al. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington\u2019s disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2023;22(6):494-504. DOI: 10.1016\/S1474-4422(23)00127-8"}],"container-title":["Mental Health Clinician"],"original-title":[],"link":[{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/14\/6\/article-p304.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/mhc.kglmeridian.com\/downloadpdf\/journals\/mhcl\/14\/6\/article-p304.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/mhc.kglmeridian.com\/downloadpdf\/journals\/mhcl\/14\/6\/article-p304.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T11:57:35Z","timestamp":1733313455000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/14\/6\/article-p304.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":34,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.9740\/mhc.2024.12.304","relation":{},"ISSN":["2168-9709"],"issn-type":[{"type":"electronic","value":"2168-9709"}],"subject":[],"published":{"date-parts":[[2024,12]]}}}